<DOC>
	<DOC>NCT01048671</DOC>
	<brief_summary>To evaluate the management of HIV-1 participants treated with antiretroviral combination therapy including the integrase inhibitor raltegravir, all across the country of France.</brief_summary>
	<brief_title>Management of Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Antiretroviral (ARV) Combination Therapy Including Raltegravir (MK-0518-138)</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Integrase Inhibitors</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>HIV Integrase Inhibitors</mesh_term>
	<criteria>Participant Infected With HIV1. Participant for whom raltegravir therapy has been decided and started less than 30 days prior to inclusion in the study. Participant who has received oral and written information about the study and who has agreed to the computer processing of his/her personal data. Participant taking part in a clinical trial to assess raltegravir. Participant in whom raltegravir treatment was started more than 30 days ago.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>HIV</keyword>
</DOC>